-
Views
-
Cite
Cite
John I. Gallin, Interferon-γ in the Management of Chronic Granulomatous Disease, Reviews of Infectious Diseases, Volume 13, Issue 5, September 1991, Pages 973–978, https://doi.org/10.1093/clinids/13.5.973
- Share Icon Share
Abstract
Bactericidal activity of phagocytic cells depends largely upon their production of highly reactive compounds via the metabolism of oxygen. A lesion anywhere in the biochemical pathway of hydrogen peroxide production potentially can cause chronic granulomatous disease (CGD). Recent work has shown that CGD results from specific abnormalities in the nicotinamide-adenine dinucleotide phosphate (NADPH) system, which includes membrane-associated proteins, NADPH, cytochrome b-558, and several cytosolic proteins. Pharmacologic alteration of phagocytic oxidative metabolism can now be achieved through use of recombinant lnterferon-γ (IFN-γ). Data from a multicenter clinical trial indicate that sustained administration of IFN-γ is effective in the management of CGD; for patients who received IFN-γ, a 72% reduction in the relative risk of serious infection was noted in comparison with the risk for patients who received placebo. IFN-γ reduced not only the number of serious primary infections but also the length of hospitalizations.